Image-empty-state.png

Shaun McNulty Ph.D.

Chief Scientific Officer

Dr. Shaun McNulty is an experienced Chief Scientific Officer, with over 25 years of experience in the biotechnology and pharmaceutical sectors. Having obtained his doctorate in kinase-mediated signalling in glioma cells, from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge, researching kinase-modulated signalling, transcription factor activation and protein expression. Shaun then held drug discovery leadership positions of increasing seniority for Pfizer and GSK, managing small molecule programmes into preclinical development and validating kinases as therapeutic targets. He worked on the Lyrica and Neurontin drug programmes and published more than thirty papers characterising signalling pathways.

Shaun moved into the Biotechnology sector in 2006, joining Syntaxin to direct their oncology discovery portfolio. He then moved to ImmBio, directing scientific collaborations and developing a fundraising strategy. As Biosceptre’s CSO since 2014, Shaun directed a portfolio of oncology candidates, obtaining regulatory approval for two candidates to enter the clinic. He is a member of the American Association for Cancer Research and the American Society of Clinical Oncology.

About Us